Navigation Links
Common BP Drug Treats Muscular Dystrophy

Johns Hopkins Researchers have shown that a drug commonly used to lower blood pressure reverses muscle wasting// in genetically engineered mice with Marfan syndrome and also prevents muscle degeneration in mice with Duchenne muscular dystrophy.

The results are reported online this week at Nature Medicine.

In 2006, a team led by Harry "Hal" Dietz, M.D., discovered that treating Marfan mice with losartan (Cozaar) dramatically strengthens the aorta, the major artery carrying blood away from the heart, and prevents enlargement and risk of bursting, a condition known as aortic aneurysm. A clinical trial to assess how effective losartan is for treating people with Marfan will launch within weeks.

"In addition to the aortic defect, children with severe Marfan syndrome often have very small, weak muscles, and adults with Marfan often can't gain muscle mass despite adequate nutrition and exercise," explains Dietz, a professor at the McKusick-Nathans Institute of Genetic Medicine at The Johns Hopkins University School of Medicine.

Dietz and his colleagues had previously discovered that many features of Marfan syndrome, including aortic aneurysm, arise from excess activity of TGF-beta, a protein that instructs cell behavior. Marfan mice have muscles containing much scar tissue between unusually small muscle fibers, which also show evidence of too much TGF-beta activity. Dietz's team reasoned that blocking the activity of TGF-beta might restore normal muscle structure and function.

First, the research team injected Marfan mice with a protein that binds TGF-beta and renders it inactive. This TGF-beta-blocking protein caused muscle fibers in these mice to grow bigger than those in untreated Marfan mice. "Not only did the muscles look bigger and better under the microscope," says Dietz, "the mice were also stronger and showed reduced fatigue."

The team then treated Marfan mice with losartan, a medication known to be sa fe in treating hypertension in all age groups and more importantly, known to block TGF-beta activity. Losartan treatment over six months "completely restored muscle architecture" and vastly improved strength, according to Dietz.

Further study pinpointed how too much TGF-beta activity leads to this weakened muscle architecture. According to Ronald Cohn, M.D., lead author on this study, normal muscle, by mobilizing muscle stem cells, can repair itself after injury. The team discovered that excessive TGF-beta blocks muscle regeneration and repair. "The simplest things can injure muscle," explains Cohn, an assistant professor of pediatrics and neurology at Hopkins. "Running a mile down the street causes microscopic tears in leg muscles, which normally go unnoticed because muscles are so efficient at repairing themselves."

Dietz's team then wondered whether the muscle improvement from blocking TGF-beta was specific to Marfan syndrome or possibly represented a strategy that could be applied to other muscle diseases such as Duchenne muscular dystrophy (DMD). Duchenne muscular dystrophy, the most common form of incurable muscular dystrophy in children, generally leads to death in early adulthood or before. DMD causes muscle fibers to be incredibly fragile. As a person with DMD ages, their muscles slowly lose the ability to regenerate and repair, which leads to loss of muscle function, explains Cohn.

TGF-beta never had been implicated as a cause of the inability to repair muscle in DMD. So the researchers examined muscles from mice genetically engineered to have DMD and found evidence of increased TGF-beta activity.

The team treated one group of DMD mice with TGF-beta-blocking protein and another group with losartan. Both groups of treated mice showed completely restored ability to regenerate muscle after injury, whereas untreated mice had large patches of scar tissue in place of muscle. Losartan treatment over many months preserved muscle architecture "over the long haul," says Dietz.

The team then measured muscle strength of untreated DMD mice as well as mice treated for nine months with losartan by connecting the muscles to tiny "force-meters" that measured contraction after an electrical stimulus. While the untreated DMD muscles were "very weak," according to Dietz, losartan-treated DMD muscles were "indistinguishable" from normal muscles in how strongly they contracted.

"We may have a real treatment alternative for a fatal disease-Duchenne muscular dystrophy-that improves both length and quality of life," says Cohn.

"For so many reasons, we're excited about these studies and their potential to transform the care of patients with both Marfan syndrome and Duchenne muscular dystrophy," says Dietz. "First, this treatment strategy comes from understanding the basic science, the molecular underpinnings of the disease. Second, the treatment has worked exceptionally well in animal models. Third, we are not dealing with a mysterious compound that was simply pulled off the shelf - losartan has already been proven safe," says Dietz.

"Furthermore, losing the ability to regenerate muscle over time is seen in many inherited and acquired muscle diseases and is even part of the normal aging process," adds Cohn. "We may only be seeing the tip of the iceberg."

Losartan first approved for use as a blood pressure medication in 1995 by the U.S. Food and Drug Administration, often is used as an alternative to other antihypertensive drugs in people who cannot tolerate other blood pressure medicines.



Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... , ... May 04, 2016 , ... May kicked off ... people across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as ... advice and focus on skin safety and health now and in the future. , ...
(Date:5/4/2016)... ... , ... Recognizing that lifestyle medicine is essential to health and healthcare, ... Katz, MD, MPH, president of the American College of Lifestyle Medicine, as their first ... gratifying,” said Katz. “There is so much opportunity to add years to lives, and ...
(Date:5/4/2016)... ... 2016 , ... Bayco Products has announced the introduction of ... in models NSP-9842XL and NSR-9844XL . , First previewed at SHOT Show ... included CR-123 batteries to produce up to 650 lumens in a variety of ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May 04, 2016 ... products, today revealed the non-toxic benefits of its Tutti Frutti line ... teething pain is just part of the story. These food-grade, silicone ... PVC-, and phthalate-free. , “Many baby toys contain BPA, harmful ...
(Date:5/4/2016)... ... 2016 , ... Fertility Centers of New England announced today the opening of ... Center provides convenient access to care for patients seeking fertility treatment in Maine. “We ... Comprehensive Care in Portland,” said Fertility Centers of New England President and CEO, Joseph ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
Breaking Medicine Technology: